Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 23086433)

1.

Continuous daily sunitinib for recurrent glioblastoma.

Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, Fine HA.

J Neurooncol. 2013 Jan;111(1):41-8. doi: 10.1007/s11060-012-0988-z. Epub 2012 Oct 20.

PMID:
23086433
2.

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).

Hutterer M, Nowosielski M, Haybaeck J, Embacher S, Stockhammer F, Gotwald T, Holzner B, Capper D, Preusser M, Marosi C, Oberndorfer S, Moik M, Buchroithner J, Seiz M, Tuettenberg J, Herrlinger U, Wick A, Vajkoczy P, Stockhammer G.

Neuro Oncol. 2014 Jan;16(1):92-102. doi: 10.1093/neuonc/not161. Epub 2013 Dec 4.

3.

Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.

Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS.

Oncologist. 2010;15(12):1329-34. doi: 10.1634/theoncologist.2010-0105. Epub 2010 Dec 8.

4.

Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors.

Goldlust SA, Cavaliere R, Newton HB, Hsu M, Deangelis LM, Batchelor TT, Gilbert MR, Lassman AB.

J Neurooncol. 2012 Apr;107(2):407-11. doi: 10.1007/s11060-011-0768-1. Epub 2011 Dec 28.

PMID:
22203237
5.

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA.

Neuro Oncol. 2010 Aug;12(8):855-61. doi: 10.1093/neuonc/noq025. Epub 2010 Mar 3.

6.

Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.

Pope WB, Xia Q, Paton VE, Das A, Hambleton J, Kim HJ, Huo J, Brown MS, Goldin J, Cloughesy T.

Neurology. 2011 Feb 1;76(5):432-7. doi: 10.1212/WNL.0b013e31820a0a8a.

PMID:
21282590
7.

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.

Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS.

J Neurooncol. 2012 Mar;107(1):155-64. doi: 10.1007/s11060-011-0722-2. Epub 2011 Oct 11.

8.

Implications of bevacizumab discontinuation in adults with recurrent glioblastoma.

Anderson MD, Hamza MA, Hess KR, Puduvalli VK.

Neuro Oncol. 2014 Jun;16(6):823-8. doi: 10.1093/neuonc/nou021. Epub 2014 Mar 3.

9.

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.

Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S.

Ann Oncol. 2001 Feb;12(2):259-66.

10.
11.

A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma.

Pan E, Yu D, Yue B, Potthast L, Chowdhary S, Smith P, Chamberlain M.

J Neurooncol. 2012 Oct;110(1):111-8. doi: 10.1007/s11060-012-0943-z. Epub 2012 Jul 26.

PMID:
22832897
12.

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ.

J Clin Oncol. 2008 Aug 1;26(22):3743-8. doi: 10.1200/JCO.2007.15.5416.

13.

The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.

Kaloshi G, Diamandi P, Cakani B, Brace G, Rroji A, Petrela M.

Tumori. 2015 Jan-Feb;101(1):41-5. doi: 10.5301/tj.5000210. Epub 2015 Feb 11.

PMID:
25702676
14.

Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme.

Muhic A, Poulsen HS, Sorensen M, Grunnet K, Lassen U.

J Neurooncol. 2013 Jan;111(2):205-12. doi: 10.1007/s11060-012-1009-y. Epub 2012 Nov 27.

PMID:
23184145
15.

Bevacizumab and daily temozolomide for recurrent glioblastoma.

Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, Bailey L, Peters KB, Friedman HS, Vredenburgh JJ.

Cancer. 2012 Mar 1;118(5):1302-12. doi: 10.1002/cncr.26381. Epub 2011 Jul 26.

16.

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA.

Neuro Oncol. 2007 Jan;9(1):29-38. Epub 2006 Nov 15.

17.

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.

Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ.

J Clin Oncol. 2007 Oct 20;25(30):4793-9. Erratum in: J Clin Oncol. 2008 Jan 20;26(3):514.

18.

Salvage therapy with single agent bevacizumab for recurrent glioblastoma.

Chamberlain MC, Johnston SK.

J Neurooncol. 2010 Jan;96(2):259-69. doi: 10.1007/s11060-009-9957-6. Epub 2009 Jul 11.

PMID:
19593660
19.

Outcome of discontinuing bevacizumab prior to malignant glioma progression.

Sherman WJ, Raizer JJ, Grimm SA.

J Neurooncol. 2013 Jan;111(1):87-9. doi: 10.1007/s11060-012-0985-2. Epub 2012 Oct 12. No abstract available.

PMID:
23065093
20.

Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.

Rahman R, Hempfling K, Norden AD, Reardon DA, Nayak L, Rinne ML, Beroukhim R, Doherty L, Ruland S, Rai A, Rifenburg J, LaFrankie D, Alexander BM, Huang RY, Wen PY, Lee EQ.

Neuro Oncol. 2014 Nov;16(11):1523-9. doi: 10.1093/neuonc/nou118. Epub 2014 Jun 23.

PMID:
24958095
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk